News
56m
Inquirer.net on MSNNew FDA chief urges suspension of new regulatory feesThe Food and Drug Administration (FDA) has urged the Department of Health (DOH) to approve the immediate suspension of an ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration ...
There is no “the” vaccine. There are at least two mRNA vaccines (Moderna and Pfizer) and a number of different non-mRNA ...
The FDA will no longer recommend annual COVID vaccinations for healthy people younger than 65. This means that if you are ...
The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...
As the Trump administration slashes the federal workforce, experts say cuts to the USDA, FDA and CDC have left the food ...
The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing ...
Instead of approving Stealth BioTherapeutics' drug for Barth syndrome, the FDA withheld its endorsement, but decided it may ...
The US Food and Drug Administration recently announced a major initiative to strengthen oversight of food additives and other ...
“Reported cases were rare but sometimes serious, with patients experiencing widespread, severe itching that required medical ...
More than 10 food items were recalled for salmonella on the FDA's recalls, market withdrawals and safety alerts list for May 2025. See full list.
The Cambridge, Mass.-based biotechnology company's drug, BEAM-302, is a liver-targeting lipid nanoparticle formulation that is designed to correct for a mutation in patients with alpha-1 antitrypsin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results